CHATEAU Registry: Clinical Outcomes After Transcatheter Aortic Valve Replacement
Recruiting
Observational Study
Aortic Valve Stenosis
Transcatheter Aortic Valve Replacement (TAVR)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 4,000 (estimated)
- Sponsor
- Eunpyeong St. Mary's Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study is a multicenter, retrospective registry study using the CHATEAU Registry. The study will evaluate patients who underwent transcatheter aortic valve replacement between January 2021 and December 2025. The purpose of the study is to assess clinical outcomes and valve performance after TAVR in real-world practice, with a focus on procedural strategies, valve-related factors, and long-term…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adults (≥18 years of age).
* Patients who underwent transcatheter aortic valve replacement (TAVR) for severe native aortic valve disease at participating centers.
* TAVR performed between January 1, 2021 and December 31, 2025.
* Availability of baseline procedural and follow-u…
Contacts